|
|
Post by adventuresome on Aug 7, 2018 9:44:24 GMT -5
I have been long over four years. Pls say again what happens if mnkd does not maintain the one dollar minimum. and your thoughts on what effect does the possible death of mnkd (which i do not believe will happen, but that's just me), on endo's prescribing afrezza?
|
|
|
|
Post by mnholdem on Aug 7, 2018 9:47:36 GMT -5
On the Nasdaq, the delisting process is set in motion when a company trades for 30 consecutive business days below the minimum bid price ($1) or market cap for that exchange.
There's a lot of noise on the internet, but I'm not the least bit worried about delisting.
Good fortune to you!  |
|
|
|
Post by traderdennis on Aug 7, 2018 11:18:05 GMT -5
On the Nasdaq, the delisting process is set in motion when a company trades for 30 consecutive business days below the minimum bid price ($1) or market cap for that exchange.
There's a lot of noise on the internet, but I'm not the least bit worried about delisting.
Good fortune to you! I agree, delisting will not be an issue. |
|
|
|
Post by lennymnkd on Aug 7, 2018 11:32:58 GMT -5
|
|
|
|
Post by sportsrancho on Aug 7, 2018 12:59:20 GMT -5
|
|
|
|
Post by babaoriley on Aug 7, 2018 15:04:06 GMT -5
From the SENS article, talking about coverage (I know, coverage, what's so important about that  ): "The Horizon BCBSNJ coverage decision is significant not only because of the promptness with which it followed the FDA’s product approval, but also because Horizon serves nearly 4 million covered lives primarily in New Jersey but also in adjacent states." Does anyone know what the status of Afrezza is with this group? Seems like somewhere we ought to make a special effort to approach, if we're not already in with them. |
|
|
|
Post by casualinvestor on Aug 7, 2018 15:27:16 GMT -5
From the SENS article, talking about coverage (I know, coverage, what's so important about that ): "The Horizon BCBSNJ coverage decision is significant not only because of the promptness with which it followed the FDA’s product approval, but also because Horizon serves nearly 4 million covered lives primarily in New Jersey but also in adjacent states." Does anyone know what the status of Afrezza is with this group? Seems like somewhere we ought to make a special effort to approach, if we're not already in with them. It's on the Prior Auth/Medical Necessity list: www.horizonblue.com/sites/default/files/pdf/PriorAuthMedicalNecessityDetermination.pdfAlso on that list: HUMALOG and NOVALOG FYI, it's pretty easy to see any plan's formulary with a quick search |
|
|
|
Post by peppy on Aug 7, 2018 17:13:40 GMT -5
From the SENS article, talking about coverage (I know, coverage, what's so important about that ): "The Horizon BCBSNJ coverage decision is significant not only because of the promptness with which it followed the FDA’s product approval, but also because Horizon serves nearly 4 million covered lives primarily in New Jersey but also in adjacent states." Does anyone know what the status of Afrezza is with this group? Seems like somewhere we ought to make a special effort to approach, if we're not already in with them. It's on the Prior Auth/Medical Necessity list: www.horizonblue.com/sites/default/files/pdf/PriorAuthMedicalNecessityDetermination.pdfAlso on that list: HUMALOG and NOVALOG FYI, it's pretty easy to see any plan's formulary with a quick search wow, every rapid acting mealtime insulin needs "Prior Authorization/Medical Necessity Determination medicine list". Is this normal? 2018 Blue Cross Blue Shield Association. All Rights Reserved. The Blue Cross Blue Shield Association is an association of independent, locally operated Blue Cross and Blue Shield companies. www.bcbs.com/the-health-of-america/about prnt.sc/j7x6kuprnt.sc/j7x5ka |
|
|
|
Post by brotherm1 on Aug 7, 2018 20:58:55 GMT -5
On the Nasdaq, the delisting process is set in motion when a company trades for 30 consecutive business days below the minimum bid price ($1) or market cap for that exchange.
There's a lot of noise on the internet, but I'm not the least bit worried about delisting.
Good fortune to you! I agree, delisting will not be an issue. Now I’m really confused. |
|
|
|
Post by peppy on Aug 7, 2018 21:06:32 GMT -5
I agree, delisting will not be an issue. Now I’m really confused. he is saying, "death becomes you." get it now? |
|
|
|
Post by traderdennis on Aug 7, 2018 22:13:06 GMT -5
I agree, delisting will not be an issue. Now I’m really confused. Delisting can take over a year. In my opinion there are still two outcomes possible and if a positive one the price will be above a dollar. |
|
|
|
Post by mytakeonit on Aug 7, 2018 22:16:55 GMT -5
Delisting? Wow, this guy just doesn't give up trying to spread FUD.
|
|
|
|
Post by brotherm1 on Aug 7, 2018 23:08:14 GMT -5
I’m not sure about that. I think that’s the way he sees it in his mind. I believe he’s giving his honest opinion. He’s a trader and probably has a set of rules he uses to base his trading methods on.
I’m in for the loooong haul. Personally I’m confident we’ll get through this cash crunch and be successful. I base my thoughts on all I’ve read over the past 2 1/2 years about mnkd and diabetes and upon 30 plus years of watching and trading dozens of small cap stocks that very often appeared to be and were in trouble. We have a great product and a very good management team - the two things I value the most in a company along with cash. We just need some Monie
|
|
|
|
Post by sayhey24 on Aug 8, 2018 5:41:35 GMT -5
I have been long over four years. Pls say again what happens if mnkd does not maintain the one dollar minimum. and your thoughts on what effect does the possible death of mnkd (which i do not believe will happen, but that's just me), on endo's prescribing afrezza? The possible death of MNKD? After putting $2.5B into this and being the most snake bit company I have ever seen including losing Al Mann in the processes, I don't think the death of MNKD is happening. After more than a dozen years we are starting to see the light at the end of the tunnel. We have seen the death of afrezza after SNY dropped it and their sales reps quickly spread the word afrezza was being pulled and scripts dried up.
Anyone with a lick of sense knows the friends of Al Mann are not going to give up now when things are finally starting to turn. The ADA2018 most talked about impact to diabetes management was afrezza and Dr. Kendall's reframing of the Affitiny-1 with the STAT pilot finding's stating A1c 8 to 6.8 with no additional hypos. Thats a game changer. The Baltimore study is wrapping up next month and I expect to see great results for the T2s. I suspect afrezza is living rent free in the heads of some BP execs including Ollie Brandicourt.
Steve has one job, get the money at the best price. He has several options but as a last gasp if the lights were really being turned off and which will not be necessary is a PIPE to existing share holders, the friends of Al. This group will little effort would provide $50M and I think Mike has most of their emails.
Mike has a single focus, close some deals. After 18 months he should be getting close.
Dr. Kendall has one primary job, get afrezza as the standard of care for both T1 and T2s.
|
|
|
|
Post by sportsrancho on Aug 8, 2018 6:57:19 GMT -5
And it’s going to piss a lot of people off:-))
|
|
): 
